Cargando…
Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322941/ https://www.ncbi.nlm.nih.gov/pubmed/22333708 http://dx.doi.org/10.1038/bjc.2011.548 |
_version_ | 1782229122743795712 |
---|---|
author | Myklebust, M P Fluge, Ø Immervoll, H Skarstein, A Balteskard, L Bruland, O Dahl, O |
author_facet | Myklebust, M P Fluge, Ø Immervoll, H Skarstein, A Balteskard, L Bruland, O Dahl, O |
author_sort | Myklebust, M P |
collection | PubMed |
description | BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a cohort of 53 anal carcinoma patients treated by radiation alone or combined with 5-fluorouracil and mitomycin C. RESULTS: Univariate analyses identified, among others, negative membranous DSG1 staining (P=0.009), negative cytoplasmic DSC1 staining (P=0.012) and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.004) to be associated with improved cancer-specific survival (CSS). On multivariate analyses positive DSG1 (membranous)+DSC1 (cytoplasmic) staining (HR 6.95, P=0.044), large tumour size and lymph node metastases (HR 6.44, P=0.004) and radiation without chemotherapy (HR 6.73 P=0.004) were associated with worse CSS. On univariate analysis, improved disease-free survival was associated with negative membranous staining of DSG1 (P=0.047), and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.025), among others. CONCLUSION: Membrane negativity for DSG1 and cytoplasmic negativity for DSC1 are favourable markers for CSS in SCCs of the anal region. |
format | Online Article Text |
id | pubmed-3322941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-33229412013-02-14 Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients Myklebust, M P Fluge, Ø Immervoll, H Skarstein, A Balteskard, L Bruland, O Dahl, O Br J Cancer Molecular Diagnostics BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a cohort of 53 anal carcinoma patients treated by radiation alone or combined with 5-fluorouracil and mitomycin C. RESULTS: Univariate analyses identified, among others, negative membranous DSG1 staining (P=0.009), negative cytoplasmic DSC1 staining (P=0.012) and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.004) to be associated with improved cancer-specific survival (CSS). On multivariate analyses positive DSG1 (membranous)+DSC1 (cytoplasmic) staining (HR 6.95, P=0.044), large tumour size and lymph node metastases (HR 6.44, P=0.004) and radiation without chemotherapy (HR 6.73 P=0.004) were associated with worse CSS. On univariate analysis, improved disease-free survival was associated with negative membranous staining of DSG1 (P=0.047), and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.025), among others. CONCLUSION: Membrane negativity for DSG1 and cytoplasmic negativity for DSC1 are favourable markers for CSS in SCCs of the anal region. Nature Publishing Group 2012-02-14 2012-02-14 /pmc/articles/PMC3322941/ /pubmed/22333708 http://dx.doi.org/10.1038/bjc.2011.548 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Myklebust, M P Fluge, Ø Immervoll, H Skarstein, A Balteskard, L Bruland, O Dahl, O Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title_full | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title_fullStr | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title_full_unstemmed | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title_short | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
title_sort | expression of dsg1 and dsc1 are prognostic markers in anal carcinoma patients |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322941/ https://www.ncbi.nlm.nih.gov/pubmed/22333708 http://dx.doi.org/10.1038/bjc.2011.548 |
work_keys_str_mv | AT myklebustmp expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT flugeø expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT immervollh expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT skarsteina expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT balteskardl expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT brulando expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients AT dahlo expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients |